A comparison of long-term entecavir and adefovir treatment for HBeAg-netative Chronic Hepatitis B patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-TNRC-11001737

Enrollment

Unknown

Registered

2011-11-27

Start date

2007-09-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis B

Interventions

1:adefovir (ADV)

2:entecavir (ETV)

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Diagnose of Chronic hepatitis B; Initial treatment of entecavir or adefovir; The duration of anti-viral treatment no less than 4 years

Exclusion criteria

Exclusion criteria: 1. presence of serum antibodies against hepatitis C virus (HCV), or human immunodeficiency virus (HIV); 2. the course of pre-antiviral agent therapy (nucleoside analogues or interferon) more than 3 months; 3. other acquired or inherited causes of liver disease; 4. coexisting serious medical disease; 5. advanced liver disease(including decompensated cirrhosis, severe hepatitis, and hepatic carcinoma).

Design outcomes

Primary

Measure	Time frame
HBV DNA;ALT;HBsAg;Resistance;	—

Secondary

Measure	Time frame
Safety;	—

Countries

China

Contacts

Public ContactHong Tang

htang6198@hotmail.com+86 18980601313

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026